|
1
|
Foss FM and Girardi M: Mycosis fungoides
and sezary syndrome. Hematol Oncol Clin North Am. 31:297–315. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kiessling MK, Oberholzer PA, Mondal C,
Karpova MB, Zipser MC, Lin WM, Girardi M, Macconaill LE, Kehoe SM,
Hatton C, et al: High-throughput mutation profiling of CTCL samples
reveals KRAS and NRAS mutations sensitizing tumors toward
inhibition of the RAS/RAF/MEK signaling cascade. Blood.
117:2433–2440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vu HL and Aplin AE: Targeting mutant NRAS
signaling pathways in melanoma. Pharmacol Res. 107:111–116. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Petit V, Raymond J, Alberti C, Pouteaux M,
Gallagher SJ, Nguyen MQ, Aplin AE, Delmas V and Larue L: C57BL/6
congenic mouse NRASQ61K melanoma cell lines are highly
sensitive to the combination of Mek and Akt inhibitors in vitro and
in vivo. Pigment Cell Melanoma Res. 32:829–841. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Uddin S, Hussain A, Al-Hussein K,
Platanias LC and Bhatia KG: Inhibition of phosphatidylinositol
3′-kinase induces preferentially killing of PTEN-null T leukemias
through AKT pathway. Biochem Biophys Res Commun. 320:932–938. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leonard D, Huang W, Izadmehr S, O'Connor
CM, Wiredja DD, Wang Z, Zaware N, Chen Y, Schlatzer DM, Kiselar J,
et al: Selective PP2A enhancement through biased heterotrimer
stabilization. Cell. 181:688–701.e16. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wlodarchak N and Xing Y: PP2A as a master
regulator of the cell cycle. Crit Rev Biochem Mol Biol. 51:162–184.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY
and Chiang CW: Regulation of phosphorylation of Thr-308 of Akt,
cell proliferation, and survival by the B55alpha regulatory subunit
targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol
Chem. 283:1882–1892. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Letourneux C, Rocher G and Porteu F:
B56-containing PP2A dephosphorylate ERK and their activity is
controlled by the early gene IEX-1 and ERK. EMBO J. 25:727–738.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gutierrez A, Pan L, Groen RW, Baleydier F,
Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C,
Pflumio F, et al: Phenothiazines induce PP2A-mediated apoptosis in
T cell acute lymphoblastic leukemia. J Clin Invest. 124:644–655.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zonta F, Pagano MA, Trentin L, Tibaldi E,
Frezzato F, Trimarco V, Facco M, Zagotto G, Pavan V, Ribaudo G, et
al: Lyn sustains oncogenic signaling in chronic lymphocytic
leukemia by strengthening SET-mediated inhibition of PP2A. Blood.
125:3747–3755. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hartung B, Sampson S and Leucht S:
Perphenazine for schizophrenia. Cochrane Database Syst Rev.
2015:CD0034432015.
|
|
13
|
Tsuji S, Yabe R, Usui T, Mizuno T, Ohama T
and Sato K: Anti-tumor effects of perphenazine on canine lymphoma.
J Vet Med Sci. 78:1293–1298. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ruvolo PP, Deng X, Ito T, Carr BK and May
WS: Ceramide induces Bcl2 dephosphorylation via a mechanism
involving mitochondrial PP2A. J Biol Chem. 274:20296–20300. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alessi DR, James SR, Downes CP, Holmes AB,
Gaffney PR, Reese CB and Cohen P: Characterization of a
3-phosphoinositide-dependent protein kinase which phosphorylates
and activates protein kinase Balpha. Curr Biol. 7:261–269. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
Rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
García-Martínez JM and Alessi DR: mTOR
complex 2 (mTORC2) controls hydrophobic motif phosphorylation and
activation of serum- and glucocorticoid-induced protein kinase 1
(SGK1). Biochem J. 416:375–385. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alessi DR, Saito Y, Campbell DG, Cohen P,
Sithanandam G, Rapp U, Ashworth A, Marshall CJ and Cowley S:
Identification of the sites in MAP kinase kinase-1 phosphorylated
by p74raf-1. EMBO J. 13:1610–1619. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou B, Wang ZX, Zhao Y, Brautigan DL and
Zhang ZY: The specificity of extracellular signal-regulated kinase
2 dephosphorylation by protein phosphatases. J Biol Chem.
277:31818–31825. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu XD, Liu YN, Zhang ZY, Ma ZA, Suo ZW and
Yang X: Spinophilin-targeted protein phosphatase-1 alleviated
inflammatory pain by negative control of MEK/ERK signaling in
spinal cord dorsal horn of rats. J Neurosci. 35:13989–14001. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Lin DH, Wang ZJ, Jin Y, Yang B
and Wang WH: K restriction inhibits protein phosphatase 2B (PP2B)
and suppression of PP2B decreases ROMK channel activity in the CCD.
Am J Physiol Cell Physiol. 294:C765–C773. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saidak Z, Giacobbi AS, Louandre C, Sauzay
C, Mammeri Y and Galmiche A: Mathematical modelling unveils the
essential role of cellular phosphatases in the inhibition of
RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma
cells. Cancer Lett. 392:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Risom T, Wang X, Liang J, Zhang X, Pelz C,
Campbell LG, Eng J, Chin K, Farrington C, Narla G, et al:
Deregulating MYC in a model of HER2+ breast cancer mimics human
intertumoral heterogeneity. J Clin Invest. 130:231–246. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Umesalma S, Kaemmer CA, Kohlmeyer JL,
Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan
F, et al: RABL6A inhibits tumor-suppressive PP2A/AKT signaling to
drive pancreatic neuroendocrine tumor growth. J Clin Invest.
130:1641–1653. 2019. View Article : Google Scholar
|
|
26
|
Taylor SE, O'Connor CM, Wang Z, Shen G,
Song H, Leonard D, Sangodkar J, LaVasseur C, Avril S, Waggoner S,
et al: The highly recurrent PP2A Aα-subunit mutation P179R alters
protein structure and impairs PP2A enzyme function to promote
endometrial tumorigenesis. Cancer Res. 79:4242–4257. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tohmé R, Izadmehr S, Gandhe S, Tabaro G,
Vallabhaneni S, Thomas A, Vasireddi N, Dhawan NS, Ma'ayan A, Sharma
N, et al: Direct activation of PP2A for the treatment of tyrosine
kinase inhibitor-resistant lung adenocarcinoma. JCI Insight.
4:e1256932019. View Article : Google Scholar
|
|
28
|
Favre B, Turowski P and Hemmings BA:
Differential inhibition and posttranslational modification of
protein phosphatase 1 and 2A in MCF7 cells treated with
calyculin-A, okadaic acid, and tautomycin. J Biol Chem.
272:13856–13863. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garcia MN, Grasso D, Lopez-Millan MB,
Hamidi T, Loncle C, Tomasini R, Lomberk G, Porteu F, Urrutia R and
Iovanna JL: IER3 supports KRASG12D-dependent pancreatic cancer
development by sustaining ERK1/2 phosphorylation. J Clin Invest.
124:4709–4722. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chu Y, Solski PA, Khosravi-Far R, Der CJ
and Kelly K: The mitogen-activated protein kinase phosphatases
PAC1, MKP-1, and MKP-2 have unique substrate specificities and
reduced activity in vivo toward the ERK2 sevenmaker mutation. J
Biol Chem. 271:6497–6501. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Farrington CC, Yuan E, Mazhar S, Izadmehr
S, Hurst L, Allen-Petersen BL, Janghorban M, Chung E, Wolczanski G,
Galsky M, et al: Protein phosphatase 2A activation as a therapeutic
strategy for managing MYC-driven cancers. J Biol Chem. 295:757–770.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Enjoji S, Yabe R, Tsuji S, Yoshimura K,
Kawasaki H, Sakurai M, Sakai Y, Takenouchi H, Yoshino S, Hazama S,
et al: Stemness is enhanced in gastric cancer by a SET/PP2A/E2F1
axis. Mol Cancer Res. 16:554–563. 2018. View Article : Google Scholar : PubMed/NCBI
|
